| Autor: |
Payne, Amanda B, Watts, Janet A, Mitchell, Patrick K, Dascomb, Kristin, Irving, Stephanie A, Klein, Nicola P, Grannis, Shaun J, Ong, Toan C, Ball, Sarah W, DeSilva, Malini B, Natarajan, Karthik, Sheffield, Tamara, Bride, Daniel, Arndorfer, Julie, Naleway, Allison L, Koppolu, Padma, Fireman, Bruce, Zerbo, Ousseny, Timbol, Julius, Goddard, Kristin, Dixon, Brian E, Fadel, William F, Rogerson, Colin, Allen, Katie S, Rao, Suchitra, Mayer, David, Barron, Michelle, Reese, Sarah E, Rowley, Elizabeth A K, Najdowski, Morgan, Ciesla, Allison Avrich, Mak, Josephine, Reeves, Emily L, Akinsete, Omobosola O, McEvoy, Charlene E, Essien, Inih J, Tenforde, Mark W, Fleming-Dutra, Katherine E, Link-Gelles, Ruth |
| Zdroj: |
The Lancet; October 2024, Vol. 404 Issue: 10462 p1547-1559, 13p |
| Abstrakt: |
Respiratory syncytial virus vaccines first recommended for use during 2023 were efficacious against lower respiratory tract disease in clinical trials. Limited real-world data regarding respiratory syncytial virus vaccine effectiveness are available. To inform vaccine policy and address gaps in evidence from the clinical trials, we aimed to assess the effectiveness against respiratory syncytial virus-associated hospitalisations and emergency department encounters among adults aged at least 60 years. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
